Beleodaq

Active Ingredient(s): Belinostat
FDA Approved: * July 3, 2014
Pharm Company: * SPECTRUM PHARMS
Category: Cancer

Belinostat (trade name Beleodaq, previously known as PXD101) is a histone deacetylase inhibitor drug developed by TopoTarget for the treatment of hematological malignancies and solid tumors.[2] It was approved in July 2014 by the US FDA to treat peripheral T-cell lymphoma.[3] In 2007 preliminary results were released from the Phase II clinical trial of intravenous belinostat in combination with carboplatin and paclitaxel for relapsed ovarian cancer.[4&a... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Beleodaq 500 mg/10ml Intravenous Injection, Powder, Lyophilized, for Solution

NDC: 68152-108

Labeler:

Spectrum Pharmaceuticals, Inc.

Beleodaq 500 mg/10ml Intravenous Injection, Powder, Lyophilized, for Solution

NDC: 69605-002

Labeler:

Cenexi - Bla

Beleodaq 500 mg/10ml Intravenous Injection, Powder, Lyophilized, for Solution

NDC: 72893-002

Labeler:

Acrotech Biopharma LLC